Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 5, 2023
Reporting Period: Event date December 5, 2023; Closing expected December 7, 2023.
Context: The Company entered into a Securities Purchase Agreement to conduct a public offering of common stock, pre-funded warrants, and common warrants. The offering is registered under an effective Form S-1.
Key Financial Metrics and Transaction Details
Offering Structure:
- Common Stock: 600,000 shares.
- Pre-Funded Warrants: 1,650,000 warrants (exercisable for 1,650,000 shares at $0.0001).
- Series C Common Warrants: 2,250,000 warrants (exercisable at $2.00, expire in 2 years).
- Series D Common Warrants: 2,250,000 warrants (exercisable at $2.00, expire in 5 years).
Pricing:
- Combined price per Common Stock + Warrants: $2.00.
- Combined price per Pre-Funded Warrant + Warrants: $1.9999.
Proceeds and Expenses:
- Net Proceeds: Approximately $3.6 million (after placement agent fees and offering expenses).
- Placement Agent Fees: 5.5% of gross proceeds (A.G.P. and Brookline Capital Markets).
- Tail Fee (H.C. Wainwright): 7.0% in cash ($303,100) and 6.0% in warrants (129,900 shares).
- Legal Expenses: Reimbursement up to $75,000 plus $15,000 non-accountable allowance.
Use of Proceeds: Working capital, general corporate purposes, research and development, trial preparation expenses, and retention/severance payments for employees.
Material Changes and Restrictions
Capital Structure Impact: The offering increases the number of outstanding shares and warrants significantly. Pre-funded warrants were utilized to prevent certain purchasers from exceeding beneficial ownership limits (4.99% or 9.99%).
Issuance Restrictions: The Company agreed to a 90-day lock-up period following the closing, restricting the issuance and sale of Common Stock or Common Stock Equivalents.
Warrant Terms: Warrants are immediately exercisable. Cashless exercise is permitted under specific conditions (e.g., if a registration statement is not effective). Fundamental transaction provisions allow for repurchase at Black Scholes Value or conversion to consideration offered to common stockholders.
Guidance, Outlook, and Risks
Outlook: Management intends to utilize the capital to advance research and development and cover trial preparation costs. The closing is contingent on customary conditions.
Risks and Contingencies:
- Closing Risk: The transaction is subject to customary closing conditions.
- Dilution: The issuance of shares and warrants will result in dilution to existing shareholders.
- Market Risk: No trading market is expected for the Pre-Funded Warrants or Common Warrants issued in this offering.
- Ownership Limits: Exercise of warrants is capped to prevent holders from exceeding 4.99% (or 9.99%) beneficial ownership.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $3.6 million net proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
- Confirm the exact number of shares issued upon exercise of pre-funded warrants and the impact on total share count.
- Monitor the 90-day issuance restriction period for potential impact on future capital raises.
- Check subsequent filings for updates on the use of proceeds, specifically regarding trial preparation and employee retention.